Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?

C Bailly, G Vergoten - Pharmacology & therapeutics, 2020 - Elsevier
Safe and efficient drugs to combat the current COVID-19 pandemic are urgently needed. In
this context, we have analyzed the anti-coronavirus potential of the natural product …

HMGB1 in health and disease

R Kang, R Chen, Q Zhang, W Hou, S Wu, L Cao… - Molecular aspects of …, 2014 - Elsevier
Complex genetic and physiological variations as well as environmental factors that drive
emergence of chromosomal instability, development of unscheduled cell death, skewed …

Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation

Y Zhou, Y Wang, J Wang, RA Stetler, QW Yang - Progress in neurobiology, 2014 - Elsevier
Intracerebral hemorrhage (ICH) accounts for 10–15% of all strokes and is associated with
high mortality and morbidity. Currently, no effective medical treatment is available to improve …

An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies

D Musumeci, GN Roviello, D Montesarchio - Pharmacology & therapeutics, 2014 - Elsevier
Abstract HMGB1 (High-Mobility Group Box-1) is a nuclear protein that acts as an
architectural chromatin-binding factor involved in the maintenance of nucleosome structure …

HMGB1 as biomarker and drug target

E Venereau, F De Leo, R Mezzapelle… - Pharmacological …, 2016 - Elsevier
Abstract High Mobility Group Box 1 protein was discovered as a nuclear protein, but it has
a⿿ second life⿿ outside the cell where it acts as a damage-associated molecular pattern …

HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury

S Tian, L Zhang, J Tang, X Guo… - American Journal of …, 2015 - journals.physiology.org
Previous studies have indicated that macrophage phenotype diversity is involved in the
progression of renal fibrosis. However, the factors facilitating M1 or M2 phenotypes and the …

Drug target identification using network analysis: Taking active components in Sini decoction as an example

S Chen, H Jiang, Y Cao, Y Wang, Z Hu, Z Zhu… - Scientific reports, 2016 - nature.com
Identifying the molecular targets for the beneficial effects of active small-molecule
compounds simultaneously is an important and currently unmet challenge. In this study, we …

[HTML][HTML] A comprehensive spectral and in silico analysis on the interactions between quercetin, isoquercitrin, rutin and HMGB1

P Shen, Y Peng, X Zhou, X Jiang, R Raj, H Ge… - LWT, 2022 - Elsevier
The intake of quercetin and its glycosides has been proven to effectively reduce the level of
high mobility group protein 1 (HMGB1) and the degree of inflammation, but the underlying …

Biobased polymeric surfactant: natural glycyrrhizic acid-appended homopolymer with multiple pH-responsiveness

Y Ma, J Hao, K Zhao, Y Ju, J Hu, Y Gao, F Du - Journal of colloid and …, 2019 - Elsevier
Even though amphiphilic natural products have been widely employed in cosmetics, food,
and pesticide formulations, the development of a compound with stimuli-responsiveness is …

Dissection of mechanisms of Chinese medicinal formula Si-Miao-Yong-an decoction protects against cardiac hypertrophy and fibrosis in isoprenaline-induced heart …

Y Zhao, Y Jiang, Y Chen, F Zhang, X Zhang… - Journal of …, 2020 - Elsevier
Abstract Ethnopharmacological relevance Si-Miao-Yong-An decoction (SMYAD) is a
traditional Chinese herbal formulation. SMYAD first appeared in the Eastern Han Dynasty …